Comparative analysis of the effectiveness of vaccines against SARS-CoV-2 3 months after revaccination
https://doi.org/10.47093/2713-069X.2022.3.1.32-35
Abstract
Since 2021, Turkmenistan has been vaccinating the population against COVID-19. The aim of the work is a comparative analisis of the effectiveness of vaccines against SARS–CoV-2 used in mass vaccination of the population in the development of population immunity.
Research materials. The blood serum of 960 people vaccinated with “Sputnik-lite” or “BIOvac” was used in the work.
Conclusion. 3 months after revaccination, 100 % of vaccinated patients have a high level of specific IgG antibodies in their blood serum. A comparative analysis of the effectiveness of two vaccines “Sputnik-lite” and “BIOvac”, showed that a longer immune response persists after the introduction of the vaccine “Sputnik-lite”.
About the Authors
N. K. Amannepesov
Ministry of Health and Medical Industry of Turkmenistan
Turkmenistan
Turkmenistan
Nurmuhammet K. Amannepesov – Minister of Health
Archabil str., 20, Ashgabat, 744036
K. H. Mavlanov
Center for the Prevention of Highly Infectious Infections of the State Sanitary and Epidemiological Service
Turkmenistan
Turkmenistan
Kemal Husainovich Mavlanov – Head
O. Annaev str., 81, Ashgabat, 744036
References
1. Amannepesov N.K., Mavlanov K., Mamedov M.A., et al. Post-vaccination population immunity against COVID-19 after vaccination with Sputnik-V”. Turkmenistan health care Journal. 2022; 2: 4–12.
2. Pawlowski C., Lenehan P., Puranik A., et al. FDA-Authorized mRNA COVID-19 Vaccines are Effective Per Real-World Evidence Synthesized Across a Multi-State Health System. medRxiv. 2021; 2(8): 979–992.e8. https://doi.org/10.1016/j.medj.2021.06.007
3. Thompson M.G., Burgess J.L., Naleway A.L., et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARSCoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers – Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(13): 495–500. https://doi.org/10.15585/mmwr.mm7013e3
4. Müller L., Andrée M., Moskorz W., et al. Age-Dependent Immune Response to the Biontech/ Pfizer BNT162b2 COVID-19 Vaccination. Clin Infect Dis. 2021; 73(11): 2065–2072. https://doi.org/10.1093/cid/ciab381
5. Herzberg J., Fischer B., Lindenkamp C., et al. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. Front Immunol. 2022; 13: 839922. https://doi.org/10.3389/fimmu.2022.839922
6. Wei J., Pouwels K.B., Stoesseret N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine. 2022; 28: 1072–1082. https://doi.org/10.1038/s41591-022-01721-6
7. Naaber P., Tserel L., Kangro K., et al. Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: A Longitudinal Prospective Study. Lancet Reg Heal Eur. 2021; 10: 100208. https://doi.org/10.1016/j.lanepe.2021.100208
8. PouwelsK.B., Pritchard E., Matthews P.C., et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 2021; 27(12): 2127-2135. https://doi.org/10.1038/s41591-021-01548-7
9. Parry H., Bruton R., Christine S. Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines. 2022; 14: 1–5. https://doi.org/10.1038/s41541-022-00432-w
Review
For citations:
Amannepesov N.K., Mavlanov K.H. Comparative analysis of the effectiveness of vaccines against SARS-CoV-2 3 months after revaccination. National Health Care (Russia). 2022;3(1):32-35. (In Russ.) https://doi.org/10.47093/2713-069X.2022.3.1.32-35
Views:
372
Email this article 